ImmunoGen, Novartis deal

ImmunoGen partnered with Novartis to discover and develop cancer therapeutics using ImmunoGen's Targeted Antibody Payload (TAP) technology. The therapeutics will consist of antibodies against targets selected by Novartis linked to a cytotoxic anti-cancer agent from ImmunoGen using the TAP technology. ...